morn summari compil research report summari comment publish roth capit pleas click headlin
comment access copi full research report includ applic disclosur
pivot manag
aug approv beyond insight
clinic commerci outlook
peanut desensit treatment dr
storag symposium spi lake citi
pleas contact salesperson
agf appl steadi growth tecnidex emerg product
agfss result came expect demonstr growth outsid core appl
market drove oper leverag ex- legal sever model importantli appl
revenu margin stabl tecnidex new product sale acceler bode
well season strong portion year agf continu explor debt
altern updat like next sever quarter
amtech report posit result moder ahead forecast good progress
stabil busi book seem reflect gener weak macro trend semiconductor
industri management cautiou near-term outlook pv busi discontinu
process sold expect renew focu around growth segment deliv improv
earn momentum beyond
dgd shine collagen supplement health food seg
long-term invest thesi darl global growth biodiesel renew diesel
continu take increas volum render fat market lift core render
profit management play activ role drive growth dgd jv valero
longer term plan call expans today capac profit dgd
probabl btc reinstat would drive cash benefit darl
result permit activ sweeney
report result line expect control effici measur oper
 mainten expect also highlight increas permit activ
maricopa support organ growth rang higher cycl believ
grow driven connect growth acquisit rate increas lift
target
solo result modestli ahead prep zongshen volum product
import disclosur regul ac certif locat end report
electra meccanica report result ahead model view quarterli financi result particularli meaning pre-
ramp stage would view initi volum product zongshen signific catalyst exampl new ceo paul
rivera start mon aug expect materi updat next quarter time review compani oper
target model delay yet anoth year lower pt
deliv mostli healthi overshadow reduct guidanc particular adjust ebitda lower
nearli midpoint leav us ask whether manag deliv ebitda margin downsid
move stock post-result highlight investor frustrat believ eventu achiev target model manag
need work regain credibl maintain buy lower pt
execut compel valuat reiter buy pt
deliv healthi instal though npv/w hit one-tim look ahead guidanc solid manag
appear sidestep labor issu notabl compani see risk volum expect unit econom normal
believ execut well valuat compel stock trade retain valu renew vs
reiter buy pt
result beat conserv guidanc higher-than-expect contribut acquir wolfskin busi strong growth
golf gear apparel manag rais lower end full year revenu guidanc reflect upsid less currenc pressur
increas ep guidanc also reflect lower interest expens neutral reflect current limit visibl long-term growth
outlook wolfskin slower trend thu far callaway core golf busi compar robust gain
keep roll rais pt maintain buy bain
follow slightli better expect result rais pt maintain buy rate estim essenti
unchang though forward visibl stronger potenti upsid estim view
result guidanc fell bit short recently-revis expect manag gener maintain full year outlook apart
firearm sale guid lower reflect organ declin outdoor near-term margin pressur ammunit maintain
neutral reflect challeng ammo end market vista still high leverag off-set sign initi progress improv outdoor
dot cross jallah ph
market close aimmun report financi oper updat signific focu aimmun lead peanut
allergi treatment manag provid updat manufactur commerci prepar well on-going effort prepar
adcom meet schedul septemb includ detail effort note believ final
prepar provid support potenti success approv launch reiter buy rate
light updat highlight report immens effort put forth pfic liver diseas rare diseas organ
recent launch pfic voic campaign increas awar pfic establish patient outreach yesterday
page
updat also learn plan tackl pediatr liver specialist field-deploy sale forc alreadi
well connect support group outlin report
amrn make hay adcom sun shine rahimi ph
yesterday amrn disclos fda notic plan hold adcom nov connect vascepa snda news took
street surpris amrn full prep mode adcom sinc day therefor walk meet fulli prime bring
home expand label report outlin adcom help rather harm vascepa new adcom member
far recept crew
recap spotlight blarcamesin henri cfa
report wednesday close busi financi updat year end sept takeaway opinion
includ rett trial continu high prioriti dsmb review open-label extens studi plan dementia program
suffici cash posit complet current clinic trial manag confirm blarcamesin anavex progress
accord previous guid timelin anticip rett pdd readout earli
 pancreat cancer aml remain focu rest butler ph
yesterday report busi financi updat second quarter compani end quarter
million expect fund oper marker lead program multitaa t-cell recogn target
antigen prame survivin current evalu pancreat cancer patient compani
intend begin phase ii trial evalu multitaa t-cell treatment aml end-of-year
 first-in-human truc pick butler ph
today provid busi financi updat end quarter total liquid suffici
fund oper guid first-in-human data lead program mesothelin-direct tcr fusion
construct treat mesothelin-posit solid tumor anticip addit expect file ind
direct program view updat timelin indic progress
zfgn let revisit guidelin fda clinic hold rahimi ph
came away zfgn updat posit outlook highlight recent fda agreement singl nonclin in-vivo studi
prove cv safeti also provid addit insight fda clinic hold review process path
go forward in-vivo top-lin data expect re-affirm confid zfgn continu dedic collabor
fda lift clinic hold
estim core saa ex-oth grew y/i roughli flat level encourag margin saa guid impli
q/q growth deceler stock retrench believ deceler risk built share price
keep watch eye deceler perhap stabilization/revers trend modestli better saas/bett hardwar
revenu basic unchang adj ebitda maintain neutral pt
mark ai miss gain traction await sharecar monet event aftahi
result mix ai revenu softer although defer revenu backlog still remain mostli unrecogn remain
encourag ai pipelin begin move beyond proof concept commit contract well sheer size
opportun balanc sheet issu still linger await potenti sharecar monet addit new cfo pure ai
compani could make share much attract investor pt
page
august asm announc financi result slightli better estim addit compani
creat addit flexibl option avino mine could benefit result thu reiter buy rate
price target
august announc financi result result somewhat expect addit
compani announc debt reduct initi benefit compani outlook near-term thu maintain
neutral rate price target
august exk report financi result view mix addit continu believ exk
pois show oper improv also advanc terronera project thu reiter buy rate
price target
panhandl oil ga inc buy pt market cap mil
report product mcfe per day top estim mcfe per day primarili due new seven-wel program
eagl ford shale came line march miner acquisit bakken shale oil produc properti financi
side reduc debt million repurchas approxim million common stock quarter
believ himx repres differenti invest opportun diversifi display sensor semiconductor vendor believ
near-term result guidanc reflect broad demand weak uncertainti across multipl segment compani believ
visibl growth recoveri remain limit despit season uptick certain segment lower price target
maintain neutral rate
nlst progress product litig front maintain buy desilva cfa
believ nlst repres differenti invest opportun emerg specialti memori technolog solut
encourag nlst complet itc trial sk hynix expect upcom commiss determin
favor catalyst also encourag nlst progress product front includ advanc new product sign
hybridimm mou larg china semiconductor concern maintain buy rate
asur integr heavi lift appear near end baldri cfa
asur result fair revenu adjust ebitda moder forecast pf ep also beat
estim near-term revenu mute shift strategi lower-margin profession servic deliveri cost
synergi seen much acquisit integr effort draw close core profit seen ramp asur exit
reiter price target buy rate
growth first posit pf ebitda quarter drive pt hike baldri cfa
page
result impress support strong organ growth first narrowli posit adjust ebitda quarter revenu growth
includ bio-storag acquisit still strong organ acceler commerci revenu grew
sequenti yr/yr total revenu attest impact even small number commerci approv custom
therapi reiter buy rate increas price target prior
strong bill signal effort acceler growth work baldri cfa
report revenu beat forecast also maintain pro forma profit fourth consecut quarter
discretionari choic acceler growth-focus spend narrow adjust ebitda versu recent high book
grew yr/yr well revenu growth rate argu see faster growth intermediate-term book
remain similarli strong outlook affirm good result reiter buy rate price target
servic solut track valuat remain discount buy searl cfa
report gener mix quarter sale toward lower end guidanc slightli consensu reflect near-
term slow cellular product declin legaci network solut howev dgii cold chain strategi continu execut
growth cellular product expect resum lower sale estim nt timing/season leav ebitda
unchang buy
earn per share y/i growth revenu million estim million profit
per share revenu million gross profit media margin pressur y/i adjust ebitda
y/i million million estim
rais strong ca servic buy searl cfa
report anoth strong beat rais even adjust one-tim benefit driven improv ca servic trend cost
satcom go forward outlook ca servic growth na row remain healthi driven increas take rate partial
off-set near-term adsb driven deploy delay ba rais sale ebitda estim higher end
new guidanc rang maintain buy rate
identiv earn per share increas y/i revenu million estim loss
per share revenu million reflect strong oper progress across board includ consecut quarter
posit adjust ebitda second consecut quarter posit cash flow oper first quarterli profit sinc
wait meaning royalti gibson cfa
lost million per share revenu adjust ebitda good proxi cash loss neg
million estim nearli million loss per share revenu million
oper expens nearli million lowest past three year mainli due reduct expens
much chip develop complet
page
